Larimar Therapeutics Inc LRMR Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$1.99 unchanged on Oct 16
Last price · Previous close $1.99
- Market cap
- At the last price
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$1.39Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$1.99unchangedFri, Oct 16 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$1.99Oct 15
- Volume6.18MOct 15 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume1.71MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $1.95 to $6.42; now $1.99
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the last price. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
LRMR trailed the S&P 500 in all 7 periods.
| Period | LRMR and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | LRMR: down 49.4% S&P 500: up 1.5% | LRMR trailed the S&P 500 by 50.9 percentage points Trailed |
| 3M | LRMR: down 45.8% S&P 500: up 1.9% | LRMR trailed the S&P 500 by 47.7 percentage points Trailed |
| YTD | LRMR: down 47.8% S&P 500: up 12.8% | LRMR trailed the S&P 500 by 60.6 percentage points Trailed |
| 1Y | LRMR: down 53.3% S&P 500: up 16.8% | LRMR trailed the S&P 500 by 70.1 percentage points Trailed |
| Long term | ||
| 3Y | LRMR: down 35.4% S&P 500: up 81.5% −13.5% vs +22.0% a year | LRMR trailed the S&P 500 by 116.9 percentage points Trailed |
| 5Y | LRMR: down 83.6% S&P 500: up 83.1% −30.3% vs +12.9% a year | LRMR trailed the S&P 500 by 166.7 percentage points Trailed |
| 10Y | LRMR: down 95.3% S&P 500: up 319.6% −26.3% vs +15.4% a year | LRMR trailed the S&P 500 by 414.9 percentage points Trailed |
$10,000 invested in LRMR 10 years ago (Oct 14, 2016) would be worth about $474 as of , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,964.
LRMR trailed the S&P 500 in all 7 periods.
| Period | LRMR and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | LRMR: down 49.4% S&P 500: up 1.2% | LRMR trailed the S&P 500 by 50.6 percentage points Trailed |
| 3M | LRMR: down 45.8% S&P 500: up 1.7% | LRMR trailed the S&P 500 by 47.5 percentage points Trailed |
| YTD | LRMR: down 47.8% S&P 500: up 11.9% | LRMR trailed the S&P 500 by 59.7 percentage points Trailed |
| 1Y | LRMR: down 53.3% S&P 500: up 15.5% | LRMR trailed the S&P 500 by 68.8 percentage points Trailed |
| Long term | ||
| 3Y | LRMR: down 35.4% S&P 500: up 75.0% −13.5% vs +20.5% a year | LRMR trailed the S&P 500 by 110.4 percentage points Trailed |
| 5Y | LRMR: down 83.6% S&P 500: up 71.2% −30.3% vs +11.4% a year | LRMR trailed the S&P 500 by 154.8 percentage points Trailed |
| 10Y | LRMR: down 95.3% S&P 500: up 258.1% −26.3% vs +13.6% a year | LRMR trailed the S&P 500 by 353.4 percentage points Trailed |
$10,000 invested in LRMR 10 years ago (Oct 14, 2016) would be worth about $474 as of , not counting dividends. The same amount in the S&P 500 would be worth about $35,813.
All-time high
$616.08
Closing high on . Now 99.7% below that record.
Split-adjusted daily closes since Jun 19, 2014.
Stock splits
1
1-for-12 on . Share counts adjust after each split.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $0.00
- Net income
- −$172.61M
- Diluted EPS
- −$1.39
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $0.00 | −$15.50M | −$0.24 |
| Q4 FY24 (Dec 31, 2024) | $0.00 | −$28.82M | −$0.46 |
| Q1 FY25 (Mar 31, 2025) | $0.00 | −$29.28M | −$0.46 |
| Q2 FY25 (Jun 30, 2025) | $0.00 | −$26.18M | $0.41 |
| Q3 FY25 (Sep 30, 2025) | $0.00 | −$47.71M | −$0.61 |
| Q4 FY25 (Dec 31, 2025) | $0.00 | −$62.50M | −$0.77 |
| Q1 FY26 (Mar 31, 2026) | $0.00 | −$29.61M | −$0.31 |
| Q2 FY26 (Jun 30, 2026) | $0.00 | −$32.78M | $0.30 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $0.00 | −$50.64M | −$2.95 |
| FY22 (Dec 31, 2022) | $0.00 | −$35.36M | −$1.37 |
| FY23 (Dec 31, 2023) | $0.00 | −$36.95M | −$0.84 |
| FY24 (Dec 31, 2024) | $0.00 | −$80.60M | −$1.32 |
| FY25 (Dec 31, 2025) | $0.00 | −$165.67M | −$2.27 |
Margins
- Gross —
- Operating —
- Net —
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$156.08MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$155.92MLast 12 months
- Capital spending$153.00KLast 12 months
Shareholder returns
- $172.77MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $156.72MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$4.96MAs of Jun 30, 2026
- Net cash$151.77MAs of Jun 30, 2026
- 4.70As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.04As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- −137.4%Last 12 months
Over the last 12 months, Larimar Therapeutics lost money: its net loss was 137.4% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −97.7%Last 12 months
Over the last 12 months, Larimar Therapeutics’s net loss was 97.7% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Larimar Therapeutics Inc
Larimar Therapeutics, Inc., is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich’s ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Pennsylvania, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
LRMR news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
LRMR stock FAQ
What is LRMR stock’s price today?
Larimar Therapeutics (LRMR) traded at $1.99 as of , unchanged from the previous close of $1.99. Over the past 52 weeks it has traded between $1.95 and $6.42.
If you invested $1,000 in LRMR 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in LRMR on would be worth about $47 as of , a total return of −95.3%. The same $1,000 would be worth $164 if invested five years ago and $467 if invested one year ago. Past performance doesn’t predict future returns.
What is LRMR’s P/E ratio?
LRMR’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$1.39).
What are LRMR’s earnings per share?
LRMR’s diluted earnings per share were −$1.39 over the four quarters to , compared with −$0.75 in the twelve months before. The latest quarter (Q2 FY26) brought $0.30 per share, against $0.41 a year earlier (how EPS works).
Does LRMR pay a dividend?
Larimar Therapeutics hasn’t paid a dividend in the last twelve months.
What is LRMR’s 52-week high and low?
Over the past 52 weeks LRMR has traded as low as $1.95 and as high as $6.42. At $1.99 as of , it is 69.0% below that high and 2.1% above the low.
What is LRMR’s all-time high?
LRMR’s highest closing price was $616.08 on , adjusted for stock splits. At $1.99 as of , it is 99.7% below that record.
Has LRMR stock ever split?
Yes, once: 1-for-12 on .
How has LRMR stock performed?
Including dividends and measured to the last price on , LRMR has returned −47.8% so far this year and −53.3% over the past year, and −83.6% over five years (−30.3% a year). Over the same periods the S&P 500, measured by SPY, returned +12.8%, +16.8% and +83.1%. Past performance doesn’t predict future returns.
What sector and industry is Larimar Therapeutics in?
Larimar Therapeutics is in the Healthcare sector and the Biotechnology industry, and is headquartered in Pennsylvania, USA.
What exchange does LRMR trade on?
Larimar Therapeutics trades on the Nasdaq under the ticker symbol LRMR. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.